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Abstract
Background: Unsafe abortion is estimated to account for 13% of maternal mortality globally. Medical abortion is a safe
alternative.
Methods: By estimating mortality risks for unsafe and medical abortion and childbirth for Tanzania and Ethiopia, we
modelled changes in maternal mortality that are achievable if unsafe abortion were replaced by medical abortion. We
selected Ethiopia and Tanzania because of their high maternal mortality ratios (MMRatios) and contrasting situations
regarding health care provision and abortion legislation. We focused on misoprostol-only regimens due to the drug’s low
cost and accessibility. We included the impact of medical abortion on women who would otherwise choose unsafe abortion
and on women with unwanted/mistimed pregnancies who would otherwise carry to term.
Results: Thousands of lives could be saved each year in each country by implementing medical abortion using misoprostol
(2122 in Tanzania and 2551 in Ethiopia assuming coverage equals family planning services levels: 56% for Tanzania, 31% for
Ethiopia). Changes in MMRatios would be less pronounced because the intervention would also affect national birth rates.
Conclusions: This is the first analysis of impact of medical abortion provision which takes into account additional potential
users other than those currently using unsafe abortion. Thousands of women’s lives could be saved, but this may not be
reflected in as substantial changes in MMRatios because of medical abortion’s demographic impact. Therefore policy
makers must be aware of the inability of some traditional measures of maternal mortality to detect the real benefits offered
by such an intervention.
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Introduction
In June 2009, the UN Human Rights Council passed a
landmark resolution recognizing preventable maternal mortality
and morbidity as a pressing human-rights issue that violates a
woman’s rights to health, life, education, dignity, and information.
Millennium Development Goal (MDG) 5 aims to reduce maternal
mortality by three quarters by 2015 [1]. Globally, approximately
67,900 women die each year as a consequence of unsafe abortion
(13% of maternal deaths) and around 5.3 million suffer temporary
or permanent disability [2,3]. Provision of safe induced abortion
would prevent many of these deaths but 26% of the world’s
population live in countries where abortion is either completely
prohibited or permitted only to save a woman’s life [4].
Sub-Saharan Africa has the world’s highest maternal mortality
ratios (MMRatio) [5]. In this region, 3.9% (range 0.0–23.8%) of
maternal deaths are due to induced abortion [6] arising from an
estimated 19 million unsafe abortions performed annually [7].
Africa accounts for 25% of all illegal abortions performed
worldwide and less than 1% of all legal abortions [8]. The
estimated proportion of all pregnancies terminated by induced
abortion in Africa is only 15%, the lowest for any continent [9].
This is partly due to strict sanctions against abortion in most
African countries, but also from a desire for larger families than
the rest of the world [9]. Africa is also one of the most dangerous
regions to have an abortion: the ratio of abortion deaths per
100,000 procedures is less than 1/100,000 in developed countries,
for developing countries is 330/100,000 and for Africa alone
averages 680/100,000 [8].
Medical abortion uses medications in place of traditional
surgical interventions to induce abortion [10]. It is a safe
procedure, with mortality rates for mifepristone-misoprostol
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abortion [12,13], although if taken late in pregnancy or in higher
doses there is a small risk of uterine rupture, hemorrhage and
possibly death (mifepristone-misoprostol [11,12], misoprostol-only
[13,14]).
Mifepristone with misoprostol are the most common drugs used,
with success rates of 94–97% [15]. Misoprostol-only is less effective
at 73–95% [15–26]. Mifepristone use in developing countries has
been extremely limited mainly due to licensing restrictions, but
also for several other reasons including the high cost of the
medication, leading to the exploration of use of a misoprostol-only
regimen, since misoprostol is widely used for treating other
conditions and is already registered in many countries, including
those with restrictive abortion laws. In some settings, it is known to
be widely accessed by women and doctors to induce abortion
illegally [27–30].
Several authors have estimated the potential impact of various
interventions on maternal mortality in order to inform decisions
on implementation and prioritize funding, many of which evaluate
safe abortion strategies [31–36]. Harper et al. used a simple model
to demonstrate the number of abortion-attributable deaths that
could be prevented if misoprostol were made readily available,
reporting that up to 68% of such deaths in Africa could be
prevented if the majority of women had access [31]. The authors
explored the impact of high (80%) and low (20%) access, assuming
that 80% of women attempt to access medical abortion during the
first-trimester. Here, we extend this approach to explore more
closely the different factors influencing a woman’s successful use of
medical abortion and its potential impact on maternal mortality
within sub-Saharan Africa, using Tanzania and Ethiopia as
examples.
Methods
To estimate numbers of deaths averted by introducing medical
abortion, we considered a range of possible pregnancy outcomes
depending upon whether the pregnancy was intended or wanted
and whether a woman sought an abortion. Figure 1 illustrates
these outcomes and how they influence each woman’s chances of
survival. Impact of medical abortion was modeled based on this
decision tree. For simplicity, the impact of spontaneous abortion
and stillbirth was ignored. Mortality and risk of failure associated
with termination during first and second trimesters were specified,
as risks of complication and death and failure rates increase later in
gestation [11,37].
Ethiopia and Tanzania were chosen for their high MMRatios,
unsafe abortion case-fatality rates and proportions of maternal
mortality attributable to unsafe abortion. These countries also
provide interesting contrasts as they differ in important areas
including abortion legislation (with Ethiopia’s law recently
liberalized) and provision of health care services (Tanzania has
higher access to antenatal care, contraception and health facility
treatment for acute respiratory infection (ARI)). Additionally, both
countries have recently licensed misoprostol for post-partum
hemorrhage [38]. Therefore access to medical abortion using
misoprostol is a real possibility because such registration improves
availability for obstetric-gynecologic conditions in general. No
ethics approval was sought for the study as all data used were
taken from published literature.
Model description
For each country, the number of women currently dying per
year from unsafe abortion is ma: the number of women dying from
all maternal causes, m, multiplied by the proportion of these
women dying from unsafe abortion, a. If medical abortion services
become available, the number of these deaths that could be
averted is limited by coverage, s1, so number of women who would
have died from unsafe abortion able to access medical abortion
becomes mas1.
We assume that all women choose medical abortion over unsafe
abortion, that no abortions are performed during the third trimester
and that women seek a medical abortion during the same trimester
that theywould havesoughtanunsafeabortion.Theeffectiveness of
a medical abortion regimen for first (e1) and second (e2) trimesters,
the proportion of medical abortions sought during the first trimester
(t) and the mortality risk associated with medical abortion by
trimester (cm1 and cm2) are used to calculate the number of women
undergoing successful medical abortion and considered ‘‘lives
saved’’ as mas1 e1t 1{cm1 ðÞ ze2 1{t ðÞ 1{cm2 ðÞ ½  .
For those women whose medical abortion fails, their survival
must also be estimated. Four potential scenarios are considered
(Figure 2a): 1) each woman carries her pregnancy to term and
experiences the same risk of maternal death as other women giving
birth in her country, so the death rate, defined as m,i sm~cb, where
cb is the MMRatio for her country removing the proportion of
maternal deaths due to unsafe abortion i.e. cb~MMRatio 1{a ðÞ ;
2) each women undergoes a second (unsafe) abortion and is subject
to the population-level case fatality rate for unsafe abortion
procedures for that country (assuming that half those failing
medical abortion in the first trimester are in the second trimester
by the time of the repeat procedure, m~
t
2
cu1z 1{
t
2

cu2); 3)
each woman undergoes unsafe abortion and dies (the assumption
being that these women were defined as originally dying from
unsafe abortion, if medical abortion was not available: (m=100%);
and 4) each woman seeks a repeat medical abortion, with the same
mortality risk as for their first procedure (same assumption
regarding trimesters as Scenario 2, m~
t
2
cm1z 1{
t
2

cm2) but
with an assumed 100% effectiveness. The women who experience
unsuccessful medical abortion yet survive (proportion 1{m) are also
considered ‘‘lives saved’’. Therefore the total number of lives saved
for women who would have died from unsafe abortion is:
L1~mas1 e1t 1{cm1 ðÞ ze2 1{t ðÞ 1{cm2 ðÞ ½ 
zmas1 1{e1 ðÞ t 1{cm1 ðÞ z 1{e2 ðÞ 1{t ðÞ 1{cm2 ðÞ ½  1{m ðÞ
ð1Þ
The MMRatio is defined as number ofmaternal deathsper 100,000
live births in the population: m=b6100,000, where b is total births/
year.TheadjustedMMRatiowiththeprovisionofmedicalabortion
services is:
Adjusted MMRation~
m{L1
b
|100,000 ð2Þ
Additional potential medical abortion users. More
women have unwanted pregnancies than attempt unsafe
abortion. If women were confident that safe and effective
induced abortion was available, more might induce abortion,
including those who would otherwise have carried to term. These
women would then face the mortality risks associated with medical
abortion instead of those associated with giving birth and numbers
of births would also be reduced. An extension to the original
model estimates the additional number of lives that could be saved
(see conceptual framework, Figure 2b).
To estimate additional medical abortions, number of births in
each country, b, is multiplied by the proportion of births that we
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abortion p, which we define as the proportion of women reporting
their births as being unwanted or mistimed. Therefore additional
demand for medical abortion is bp. We assume medical abortion
access is the same or lower for this group of women, s2, compared
with those who would have undergone unsafe abortion. Therefore
Figure 1. Decision tree of outcomes of pregnancy according to whether medical abortion services are available. Solid lines represent
choices available to all women; dotted lines represent choices available to women where medical abortion services are available. * Some intended
pregnancies may still result in induced abortion due to fetal abnormalities.
doi:10.1371/journal.pone.0013260.g001
Figure 2. Schematic illustrating method of estimating deaths due to unsafe abortion averted by introducing medical abortion,
representing a) the reduction in deaths from unsafe abortions averted and b) the reduction in deaths from the risk associated with
pregnancy going to term, for additional potential users of abortion services. For b), deaths averted are the difference between number of
deaths from route 1), where medical abortion is not available, and route 2) where they are available. Fractions for each bar are not drawn to scale.
* Defined as women who would have accessed unsafe abortion services but preferentially seek medical abortion services, if available. ** Assumes that
a repeated medical abortion is 100% effective.
doi:10.1371/journal.pone.0013260.g002
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that this group of women seek medical abortion during the first
trimester in the same proportion as women who seek unsafe
abortion (t). Number of lives saved depends on the mortality
difference between carrying to term and undergoing medical
abortion (cb{cm1,cb{cm2), and the effectiveness of medical
abortion (e1,e2). Therefore total deaths averted for women
accessing medical abortion services who would otherwise have
given birth is
L2~bps2 te1 cb{cm1 ðÞ z 1{t ðÞ e2 cb{cm2 ðÞ ½ 
zbps2 t 1{e1 ðÞ z 1{t ðÞ 1{e2 ðÞ ½  cb{s ðÞ
ð3Þ
where s is analogous to the m term in equation (1) and is defined
depending on one of two scenarios: i) each woman carries to term
and experiences the same risk of maternal death as other women
giving birth in her country, cb; and ii) each woman seeks a repeat
medical abortion (with assumed 100% effectiveness second time)
with the mortality risk for medical abortion (same assumption
regarding trimesters as Scenarios 2 and 4, s~
t
2
cm1z 1{
t
2

cm2).
There are no scenarios where women seek unsafe abortion because
this group of women represents those who would have given birth
rather than seek unsafe abortion. The total number of lives that
could be saved through introducing medical abortion is therefore:
L3~L1zL2 ð4Þ
The MMRatio now changes because number of births is
substantially altered by providing medical abortion to women who
would otherwise have given birth (we assume that the small change
in births for Scenario 1, where women with failed medical abortions
carry to term, has a negligible effect on the MMRatio and is ignored
here). Births per year per country with medical abortion provision,
bm,i sd e f i n e da sbm~b 1{ps2 te1z 1{t ðÞ e2 ðÞ ½  if we assume
scenario i) or bm~b 1{ps2 ðÞ for scenario ii). The MMRatio is:
Adjusted MMRatio~
m{L3
bm
ð5Þ
Parameterization
Plausible parameter values and ranges were arrived at through a
literature search (Table 1). A fuller description of parameter value
justification is given in Supplementary Text S1.
The proportions of women with access to medical abortion, s1
and s2, depend on the coverage achieved. To fully explore the
potential of this intervention, the entire range of possible values (0–
100% access) was investigated. Proportion of women accessing
other health services such as antenatal care, family planning
services and primary healthcare may indicate the possible
coverage rates achievable for medical abortion if it were made
available through these pre-existing health care service delivery
networks (see Table 1). In the absence of empirical data, we
assume s1~s2 i.e. same access for all women, although unsafe
abortion users may have higher access rates than other women (for
example being more likely to live in urban areas).
Results
Figure 3 illustrates the number of women’s lives that could be
saved by introducing medical abortion using our model. Feasible
coverage scales are indicated on the figure. Because misoprostol-
only may be a more feasible and accessible regimen for medical
abortion in developing countries, primarily due to the cost of
mifepristone, we chose to present results for a misoprostol-only
regimen for our principle results.
Assuming that many unwanted/mistimed pregnancies that
would have gone to term may be terminated through medical
abortion saves thousands more women’s lives per year than
assuming an impact on unsafe abortion users only (1093 and 1587
more lives saved/year for Tanzania and Ethiopia respectively
(2122 and 2551 saved in total), with coverage assumed at family
planning service coverage levels: 56% and 31% respectively).
However, these benefits are not reflected in the MMRatio
reductions (assuming central MMRatio estimates, Table 1): an
8% reduction when only unsafe abortion users are considered
compared to a 7% reduction when all potential users are included
for Tanzania (4% and 3% figures for Ethiopia, respectively). The
utilization of medical abortion services by women who would
otherwise have carried to term decreases the birth rate; therefore
the impact of lives saved on the MMRatio is reduced. The
relationship between the MMRatio and coverage (Figure 3b) is not
quite linear, yet considering all potential medical abortion users,
each 10% increase in coverage broadly confers a 1.0–2.0%
decrease in MMRatio for each country, saving 379 (Tanzania) and
823 (Ethiopia) women’s lives.
Model sensitivity
Choice of regimen. The number of lives saved using
misoprostol-only remains substantial (Figure 4a). For both
Tanzania and Ethiopia, using central estimates for effectiveness
of these regimens and assuming 100% access to medical abortion,
misoprostol-only saved 13% fewer lives than mifepristone-
misoprostol and mifepristone-misoprostol extends the reduction
in MMRatio from 13% (misoprostol-only) to 16%.
Outcomes for women failing medical abortion. Within
the model, women are subject to different outcomes depending on
the scenarios adopted for failed medical abortions (as describe in
the Methods). Sensitivity of lives saved and MMRatio estimates to
these assumptions are shown in Figure 4b for Tanzania. Benefits of
medical abortion are not sensitive to differences between scenarios
1, 2 and 4: these vary the future of women who would otherwise
have had an unsafe abortion and died, and in these scenarios, the
mortality risks for these women are broadly similar (that associated
with giving birth, having an unsafe abortion or having a repeat
medical abortion, respectively – even though unsafe abortion
mortality risk is far higher than the other two, it is much lower
than the 100% mortality of scenario 3). In contrast, scenario 3
assumes all these women would die as a result of unsafe abortion,
and so mitigates the impact of medical abortion quite substantially.
Benefits are also sensitive to the future of women who would
otherwise have carried to term who have a failed medical abortion
(scenarios i and ii), primarily because this is such a large group of
users.
Proportion of maternal mortality that is abortion-
related. Benefits are also highly sensitive to estimates of this
assumption (Figure 4c), highlighting the importance of collecting
cause-specific maternal mortality data at a national level, despite
the methodological challenges.
Discussion
Thousands of lives could be saved by introducing medical
abortion in Ethiopia and Tanzania, reducing their national
MMRatios. Universal medical abortion coverage reduces MMRa-
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10% increase in coverage broadly conferring a 1.0–2.0% decrease.
This constitutes considerable progress towards MDG 5. The
political climate towards abortion in Africa is showing signs of
reform, with Ethiopia recently having relaxed restrictions on
abortion provision and Ghana having approved national stan-
dards and guidelines for safe abortion that include medical
abortion. The Obama administration’s reversal of the ‘‘global gag
rule’’ now permits federal funding to be awarded to organisations
that offer abortions. Availability of misoprostol has also increased
with its registration in several African countries for use in many
obstetrics and gynaecology indications. Therefore access to
medical abortion looks set to increase substantially.
To our knowledge this is the first model to explore the wider
social impact of introducing legal medical abortion, by examining
its uptake by women who would otherwise have carried to term, as
well as women who would have undergone unsafe abortion. In
countries where a high proportion of maternal mortality is due to
unsafe abortion, the reduction in MMRatio could be dramatic if
sufficient coverage could be achieved. If the higher estimates for
Ethiopia’s abortion-attributable-maternal mortality are correct
(35%), the universal availability of misoprostol could reduce
Ethiopia’s MMRatio from 720 to 528, giving it a lower MMRatio
than Bangladesh, a country 32 places above Ethiopia on the
Human Development Index [39]. Even assuming low abortion-
attributable-maternal mortality (3.9%), Ethiopia could save
upwards of 6500 lives annually with universal access.
We found that substantial numbers of women’s lives saved by
provision of medical abortion was not always reflected in great
reductions in MMRatios, because if women who would otherwise
have given birth use these services, the birth rate may alter
considerably. The reduced birth rate implied by our model is likely
an overestimate, as many women with mistimed pregnancies who
terminate may have additional, future pregnancies, and not all
Table 1. Model parameter descriptions and estimates, with sources.
Symbol Parameter description Tanzania Ethiopia Sources
m Maternal mortality (deaths/year) High estimate 17,789 29,944 Middle estimates [39]; upper
and lower estimates derived
from b and MMRatio range.
Middle estimate 13,000 22,000
Low estimate 8,484 14,056
a Proportion of maternal mortality
that is abortion-related
Continental
estimate
3.9% 3.9% [6]
Regional estimate 17% 17% [2]
Country estimate 21% 35% [50,51]
s1, s2 Proportion of women previously undergoing
unsafe abortion (s1) or previously giving birth
(s2) who have access to medical abortion.
Antenatal care
coverage
95% 28% [40,52]
Family planning
services coverage
56% 31%
Primary healthcare
coverage*
57% 19%
e1,e2 Medical abortion effectiveness Misoprostol
only: 1
st trimester
85%
(73–92%)
85%
(73–92%)
[15–26,31,53,54]
2
nd trimester 80%
(65–85%)
80%
(65–85%)
Mifepristone-misoprostol:
both trimesters
96%
(94–97%)
96%
(94–97%)
cm1,cm2 Mortality associated with medical abortion 1
st trimester 0.0001%{ 0.0001%{ [55]
2
nd trimester 0.0024%{ 0.0024%{
cu1,cu2 Mortality associated with unsafe abortion 1
st trimester 0.0852%{ 0.0852%{ [2,8]
2
nd trimester 1.7032%{ 1.7032%{
t Proportion aborted pregnancies
terminated in 1
st trimester
62%
(60–85%)
62%
(60–85%)
[56,57]
p Proportion of pregnancies mistimed/unwanted 21.8% 33.8% [40,52]
b Total births/year 1,368,421
{ 3,055,556* Derived from estimates
of MMRatio and m [39]
MMRatio Maternal mortality ratio (maternal
deaths/100,000 live births)
950
(620–1300)
720
(460–980)
[39]
UN – United Nations; UNFPA – United Nations Population Fund; UNICEF – United Nations Children’s Fund; WHO – World Health Organization.
*Approximated by percentage of children ,5 years for whom treatment was sought from a health facility or provider (excluding pharmacies, shops and traditional
practitioners) for symptoms of acute respiratory infection.
{Figures for total births/year are in relatively good agreement to those derived from estimates of birth rate and population size for Tanzania and Ethiopia quoted in the
CIA World Fact Book (derived estimates of 1,412,486 and 2,879,751 births/year for Tanzania and Ethiopia, respectively) [58].
{Calculated figures; see Supplementary Text S1 for details. Calculations are based on proportion of aborted pregnancies terminated in the first trimester, t, being 62%;
where this value is varied in sensitivity analysis, these values are recalculated accordingly.
doi:10.1371/journal.pone.0013260.t001
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seek a medical abortion. However our analysis highlights that the
success of medical abortion in reducing numbers of maternal
deaths may not be adequately reflected in MMRatio statistics.
The area of greatest uncertainty in our simulation is the likely
coverage of medical abortion services in each country, were it to
be legalized (and therefore we have presented figures displaying
medical abortion benefits using a continuous scale of coverage). An
unwanted or mistimed pregnancy does not necessarily imply that a
woman would terminate given the availability of medical abortion
services. It is difficult to anticipate how introduction of legal
abortion services might affect abortion-seeking behaviour in these
settings. The use of family planning as a proxy for access to
medical abortion could be problematic as one would assume that
women with unwanted pregnancies are the same women without
access to contraception. We would argue that the barriers and
motivations involved in contraceptive use are significantly different
from that of abortion. Access to contraception must be continuous,
motivation to contracept must be sustained, and side effects such
as changes to the menstrual cycle must be tolerated over time.
However, with abortion access is ‘‘one-off’’, motivation is
heightened and one could argue that the gravity of an unwanted
pregnancy for many women would mean that potential side effects
would be more tolerable. The potential for medical abortion to be
distributed at antenatal clinics by midwives may mean that up to
95% of Tanzanian women could access medical abortion [40].
Figure 3. Relationship between hypothetical coverage level of medical abortion services and a) number of women’s lives saved per
year and b) the MMRatio for Tanzania and Ethiopia. All scenarios assumed medical abortion uses misoprostol-only (effectiveness 85% first
trimester, 80% second trimester); that coverage of medical abortion services is the same for women who would have had an unsafe abortion and
those who would have gone to term; proportion of maternal mortality that is abortion-related is 17% (regional estimate) and proportion of
pregnancies which are unwanted/mistimed is 21.8% for Tanzania and 33.8% for Ethiopia. We assume a conservative estimate of lives saved by
showing the worst case scenario: Figure 2a Scenario 3, Figure 2b Scenario i. That is, of those women whose medical abortion fails who would
otherwise have died from unsafe abortion, 100% are assumed to die (from seeking a second, but unsafe, abortion). Women whose medical abortion
fails who would otherwise have gone to term are assumed not to seek a second abortion of either type, and carry the same mortality risk associated
with a pregnancy going to term.
doi:10.1371/journal.pone.0013260.g003
Medical Abortion in Africa
PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13260However, Ethiopia has much weaker healthcare systems and
therefore alternative means for distribution and availability should
be explored.
Coverage will also depend on the proportion of health care
workers willing to provide medical abortion. It is difficult to
anticipate this percentage because there is not much research on
this topic in Africa [41]. We found studies of provider support that
ranged from 6% to 80%. Research in KwaZulu Natal, South
Africa in 2000 showed that only 6% of nurses supported abortion
on request (18% and 6%, respectively). However, a clear hierarchy
of support was observed: a majority of nurses (56%) supported
abortion in the case of rape or incest, or if the continued
pregnancy would endanger a woman’s health (61%, respectively),
but few supported abortion for social or economic reasons [42].
However, research in South Africa has shown that it is possible to
change attitudes, with 70% of respondents reporting behavioural
changes six months after the workshop and 93% reporting
increased compassion for women seeking abortion services [43]. In
Ghana 80%, of physicians favoured the establishment of safe
abortion units within national health facilities. Of these, 36% were
willing to take part in counselling only, 45% were prepared to
carry out abortions, and 19% said they would play no role in these
units [44]. There is anecdotal evidence that providers prefer
medical abortion because the women take the tablets themselves
and thus they, rather than the provider, induce the abortion.
The number of women able to obtain a successful medical
abortion is also contingent upon timely access. Educating women
on how to detect a pregnancy early and where to access
appropriate services quickly will be key to maximizing the impact
of this intervention. Medical abortion services could be socially
marketed as is done with other commodities such as contracep-
tives, bednets and oral rehydration salts, but the political sensitivity
in many countries to abortion services makes this unlikely.
There are many limitations to our analysis. For simplicity, the
model does not include spontaneous abortion and we assumed
that a second medical abortion after a first (failed) procedure
would be 100% successful. We assumed a low mortality for
medical abortion based on data from the United States, but this
rate (and rate of complications such as uterine rupture) may
increase within developing countries if women take misoprostol in
larger doses or late in pregnancy [45], or if they could not access
post-abortion care. The lack of available data on the prevalence of
Figure 4. Sensitivity of model output (lives saved per year and MMRatio by medical abortion coverage rate) to different model
assumptions and parameter values. a) Effectiveness of medical abortion regimen, for Tanzania: comparing misoprostol-only (estimated
effectiveness 85% range 73–92% first trimester, 80% range 65–85% second trimester) with misoprostol plus mifepristone (estimated effectiveness
96% range 94–97%, both trimesters). b) Scenarios for those women who experience an unsuccessful medical abortion (see Figure 2 and Methods for
descriptions of each scenario). c) Proportion of maternal mortality that is abortion-related, comparing national, regional and continental estimates.
Results are for impact of medical abortion in terms of reduced unsafe abortions plus additional potential users. MMRatio graphs use central MMRatio
estimate only. For a) and c) we assumed a conservative estimate of lives saved by showing the worst case scenario: Figure 2a Scenario 3, Figure 2b
Scenario i.
doi:10.1371/journal.pone.0013260.g004
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demonstrates the need for further research.
Our analysis involved various assumptions regarding outcomes
after unsuccessful medical abortions, explored through scenario
analysis. Success rates could be improved through the implemen-
tation of effective protocols which administer second doses of
misoprostol or mifepristone-misoprostol regimens, or refer women
to hospitals for surgical procedures.
Additional users in the form of women who give birth but feel
their pregnancy was unwanted/mistimed is likely overestimated,
as not all these women would necessarily seek a medical abortion.
A further group of additional potential users that are excluded for
simplicity are women who would have undergone an unsafe
abortion but survived, who would preferentially use medical
abortion services. Data are lacking on total numbers accessing
unsafe abortions in these settings: while an estimated 19 million
unsafe abortions are performed annually in sub-Saharan Africa
[7], there is considerable uncertainty surrounding this estimate.
Furthermore the mortality risk of medical abortion is low
compared with that for unsafe abortion, so additional numbers
of deaths attributable to medical abortion from this group would
be low; however uptake of medical abortion by this group would
likely have a considerable impact on maternal morbidity.
Our analysis is limited to predicting the impact of a single
intervention in reducing maternal mortality, but there are
alternatives, such as increasing access to different termination
methods, including manual vacuum aspiration. In particular,
expanding access to family planning services would circumvent the
need for abortion services in many cases. Family planning
combined with safe abortion provision has been predicted to be
the most cost-effective method of reducing maternal mortality in
Mexico [33]. We can also predict that family planning would lead
to a substantial reduction in maternal mortality, since the most
lives saved through medical abortion provision predicted by our
model was among women with unwanted pregnancies who would
otherwise have continued to term.
While unsafe abortion is ranked as the fourth most common
cause of maternal mortality worldwide, it is listed as the number
one cause of maternal morbidity [46], with estimates suggesting 78
cases of temporary or permanent disability for every unsafe
abortion-related death [2,3]. Unsafe abortion has been linked to
an increased risk of ectopic pregnancy, premature delivery, and
spontaneous abortions in subsequent pregnancies [4]. The full
impact of unsafe abortion is therefore not limited to the number of
directly attributable deaths. We did not evaluate the disability-
adjusted life years that could be saved by making medical abortion
available due to lack of data. More research is required to assess
the absolute costs of unsafe abortion because introducing medical
abortion is likely to have positive effects reaching far beyond
mortality statistics. It is widely recognized that interventions
providing safe abortion services decrease costs to the health system
through reducing complications from unsafe abortion [34,47]. In
some countries as many as two in three maternity beds are taken
up by women hospitalized for treatment after an unsafe abortion
and up to half of all ob-gyn budgets can be spent on this problem
alone [4]. In Tanzania the cost of treating a woman with
complications from unsafe abortion is over seven times the overall
Ministry of Health budget per head of the population [4]. Medical
abortion can serve only to increase cost effectiveness as
expenditure on clinical personnel and facilities can be minimized.
Introducing medical abortion in countries with high abortion-
related mortality is a feasible step towards achieving MDG 5, yet
interventions that tackle other causes of maternal mortality must
not be neglected [48]. However, many of these interventions
require substantial funding and resources. Medical abortion does
not require skilled health workers for administration, can be easily
provided outside health centers, and is portable and easily stored
meaning it can reach even remote rural areas. Several studies have
demonstrated that mid-level providers can provide abortion
services, including the diagnosis of early pregnancy and ectopic
awareness safely and effectively [49]. While safe abortion services
in any form would save women’s lives, medical abortion offers
resource-poor countries the tools to achieve this with minimal
expenditure.
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